(PRWEB) January 29, 2015
The global transcriptomics market is poised to grow at a CAGR of 13.7% from 2014 to 2019. Technological advancements, increasing investments in research and development, increasing government and private funding, and growing preference for personalized medicines are some of the major factors driving the growth of this market. However, the market also faces certain challenges in terms of high capital investment costs that limit the adoption of transcriptomics products, lack of skilled professionals and effective bioinformatics tools for data analysis. These challenges may hamper the growth of the transcriptomics market in the coming years.
Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/trancriptomics-market-240344576.html
Based on utilization of advanced technology, PCR accounted for more than 45.3% of the global transcriptomics market in 2013. However, sequencing technologies market is expected to grow at the highest CAGR of 14.3% during the forecast period of 2014 to 2019. A majority of the growth in this segment is attributed to rising demand for these technologies from academic research and government institutes. Increasing application of transcriptomics in drug discovery is driving the demand for transcriptomic technologies in the pharmaceutical and biotechnology industry. Based on the type of product, the reagents account for the largest share of approximately 53.6% of the global transcriptomics market in 2013. Transcriptomic instruments are priced higher than the reagents. However, frequent purchase of consumables including reagents has led to its greater market share and robust growth rate during the forecast period.
For Report Inquiry @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=240344576
There is an extensive use of transcriptomics in the academic research and government institutes which account for highest share of 49.2% of the transcriptomics market for various research applications followed by pharmaceutical and biotechnology companies. Similarly, the drug discovery and research contributes major share of x64.1% to the total market followed by clinical diagnostics with 28.6% share of the global market. However, the pharmaceutical and biotechnology companies, and clinical diagnostics segment are expected to grow at a higher CAGR during the forecast period.
Thermofisher Scientific Inc. (Life Technologies) (U.S.) was a leading player in the transcriptomics market in 2013 with 30.2% share in the global market. The leading position of this company in this market was mainly attributed to its strong presence in the PCR and sequencing market. Over the years, the company has maintained its leading position through a strong distribution network across North America, Europe, Middle East and Africa, Asia-Pacific, and Latin America. Moreover, the company focuses on new product launches and acquisitions as its key business strategies, to ensure its growth in the global transcriptomics market. For instance, in 2014, Thermofisher acquired Life Technologies Corporation which has led to the enhancement of PCR product portfolio of the company.
Illumina Inc. (U.S.) was another prominent player in the global transcriptomics market with 21.5% share in 2013. The dominant position of this company is mainly attributed to its diverse product portfolio offering various products for RNA sequencing.
For PDF Manual @ http://www.marketsandmarkets.com/pdfdownload.asp?id=240344576
Apart from these two, Hoffmann-La Roche (Switzerland.) is also a prominent player in the transcriptomics market with extensive product portfolio for RNA analysis. Affymetrix Inc. (U.S.) and Agilent Technologies Inc. (U.S.) are the other prominent players in the microarray market. However, with the transition from microarrays to next generation sequencing the microarray businesses of these players have been adversely affected which has negatively impacted the market position of these players.
Some of the other players in this market are GE Healthcare (U.S.), Qiagen N.V. (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Sigma Aldrich (U.S.) and Fluidigm Corporation (U.S.).
MarketsandMarkets is the world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 full time analysts and SMEs at MarketsandMarkets are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, and identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, “RT” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North – Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog@ http://mnmblog.org/market-research/healthcare/biotechnology
Related Bioinformatics Press Releases